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trated with an example that highlights pitfalls involved with more simplistic ap-
proaches.
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OBJECTIVES: To describe the theoretical approach suggested to close the gap be-
tween recommendations and implementation of clinical practice guidelines
(CPG’s) in Colombia, called harmonization of CPG’s with Public Policy. METHODS:
Perspective paper. A theoretical approach is suggested to harmonize CPG’s recom-
mendationswith public policy. RESULTS: Public policies often don=t get the desired
results, because there is a gap between the decision and the reality. There is a
conceptual and temporal separation between policy formulation and implemen-
tation of decisions, CPG’s are tools to improve quality in the delivery of health
services. However a process od harmonization between recommendations and
implementation with public policy is requested. For this a process of three phases
should be developed: 1) To do a review of existing regulations on health and on the
specific issue of the CPG to harmonize the current policy with recommendations
and identify barriers to the implementation process; 2) To adjust recommenda-
tions of CPG’s to eliminate the barriers encountered with the standards; 3. To state
a negotiation processwith all actors involved in the implementation of the CPG’s at
different levels of care, to generate commitment with them, proposals for changes
in policy and / or administrative, and if it is necessary, to remove barriers
CONCLUSIONS:Harmonization of CPG’s with public policy is a fundamental tool to
improve their implementation. Three phases are proposed. Negotiation could be
the most important one.
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SOCIETAL PERSPECTIVE IN ECONOMIC EVALUATION: CONFUSIONS AND
HIRA’S RECOMMENDATION
Bae S, Lee S, You MY
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BACKGROUND: Current HIRA’s guideline recommends that economic evaluation
(EE) analysis should take societal perspective, yet the inconsistency in current
guideline has beennoted by the industry side. The purpose of this study is to review
current theoretical trends and discuss the needs of updating HIRA’s current
recommendations.METHODS: To identify the needs of EE guideline revision, HIRA
has reviewed currently updated foreign EE guidelines, and discussed recent theo-
retical trends. In addition, survey results from pharmaceutical companies as well
as decision makers regarding current recommendation were considered. Experts
meetings and working group meetings with industry people were held to share
each party’s perspectives. RESULTS: Pharmaceutical industry suggested that cur-
rent recommendation of taking societal perspective while submitting indirect cost
(especially productivity cost) separately is confusing. Canada (CADTH) has recently
updated its perspective as “publicly funded health care system”, and UK (NICE) has
recommended to take payer(NHS and PSS)’s perspective. Inconsistencies in soci-
etal perspective have also discussed in previous studies and ISPOR consensus
paper. CONCLUSIONS: Given that EE guideline should provide clear minimum
standards for submission parties, a need to clarify current “societal” perspective
has been agreed by relevant parties. “Limited” societal perspective has been pro-
posed to reduce unnecessary confusionswhile reflecting current practice patterns.
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PREVALENCE-BASED VERSUS INCIDENCE-BASED ECONOMIC EVALUATIONS
FOR THE ASSESSMENT OF NEW HEALTH CARE INTERVENTIONS
Mauskopf JA
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OBJECTIVES: To compare the usefulness to decision makers of prevalence-based
versus incidence-based economic evaluations of new health care interventions
METHODS: Comparison of evaluation methods by: population included, time ho-
rizon, outcomes measured, adherence to economic principles, and usefulness to
decision makers. RESULTS: An incidence-based economic evaluation follows a
disease cohort for the duration of the disease and estimates discounted costs and
health gains with alternative interventions. The cost-effectiveness ratio is based
on individual utility maximization and provides information to decision makers
about the efficiency of a new healthcare intervention compared to societal willing-
ness to pay for health gains. It does not estimate annual budget impacts. It gener-
ally does not capture indirect effects on the population. A prevalence-based eco-
nomic evaluation provides estimates of costs and health benefits for the total
population for one year or cumulated over a longer time horizon. The estimated
ratio of cumulative costs and health benefits is not based on economic principles.
Appropriate threshold values for these ratios are those based on a percentage of
Gross Domestic Product as recommended by the World Health Organization. The
prevalence-based cost-effectiveness ratio provides information to decisionmakers
on the affordability of the intervention and the value for money over the selected
time horizon. A prevalence-based analysis can take into account indirect effects of
health care interventions and is, therefore, frequently used for economic evalua-
tions of vaccine programs. CONCLUSIONS: Prevalence-based economic evalua-
tions might be of greater use to health care decision makers than incidence-based
evaluations because, in addition to estimates of value for money, they provide
estimates of affordability and allow comparison of all types of health care inter-
ventions. Threshold values based on economic principles, however, are not appli-
cable for ratios generated using the prevalence-based approach.
DISEASE-SPECIFIC STUDIES
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: A lower rate of hypoglycemia occurred in a Phase 3 trial in T2DM
patients receiving saxagliptin compared to glipizide (sulfonylurea (SU)) added to
metformin. The clinical trial included patient-reported and physician-reported hy-
poglycemia events. The objective of this study was to compare the rates of hypo-
glycemia events that required medical attention in actual clinical practice.
METHODS: MarketScan health care claims data was used to identify patients who
initiated saxagliptin or SU. During the 6 months prior to initiation, patients were
required to have a prescription (Rx) for metformin and no saxagliptin, SU, or other
diabetes Rx. Patients were followed for 4 months to assess the rates of hypoglyce-
mia. During follow-up, patients were required to have at least onemoremetformin
Rx and one additional saxagliptin/SU Rx and no other diabetes Rx. A hypoglycemia
event was defined as a diagnosis of hypoglycemia on an outpatient or emergency
room claim or principal diagnosis on a hospital claim or an outpatient glucagon
injection. SU patients were matched to saxagliptin patients (5 to 1) using propen-
sity scores. The rate ratio was further adjusted for covariates that were not bal-
anced between the matched cohorts using a Poisson regression model. RESULTS:
There were 1,567 saxagliptin, 21,025 SU, and 7,835 propensity-matched SU pa-
tients. The rate of hypoglycemia in the saxagliptin cohort was 1.74 per 100 PY
versus 6.68 in the SU cohort (rate ratio 0.31, 95% CI: 0.14 – 0.60) and 4.45 per 100 PY
in thematched SU sub-group (rate ratio 0.39, 95% CI: 0.17 – 0.77). After multivariate
adjustment, the rate ratio was 0.37 (95% CI: 0.19 – 0.74). CONCLUSIONS: In real
world practice, as was demonstrated in a randomized controlled trial, saxagliptin
patients had a lower risk of hypoglycemia than SU when added to metformin.
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OBJECTIVES:To assess the benefits andharms of vitamin B and/or its derivatives in
patientswith diabetic kidney disease (DKD).METHODS:Wesearched the Cochrane
Renal Group’s Specialized Register CENTRAL; MEDLINE OVID SP; Hand searching of
renal journals and conference proceedings; EMBASE OVID SP; the International
Clinical Trials Register (ICTRP) Search Portal & ClinicalTrials.gov. Randomized con-
trolled trials (RCTs) comparing vitamin B and/or its derivatives with placebo, no or
active treatment, in patients with DKD were included. RESULTS: Out of 56 identi-
fied studies, four studies were found to be suitable for inclusion. A total of 745
participants were randomized to either vitamin B derivatives (benfotiamine (300
mg TID), thiamine (300 mg OD), vitamin B12 (500 mg OD), folic acid (2.5 mg OD),
vitamin B6 (25 mg OD)) or placebo or active control. Treatment duration ranged
from 3 months to 36 months. We found that none of those derivatives improved
kidney function: improved creatinine clearance (Mean difference (MD) 2.00, 95% CI
-21.78 to 25.78, P 0.87), decreased serum creatinine level (MD 1.00, 95% CI -7.88 to
9.88, P  0.83), reduce level of urinary albumin excretion level (MD: -16.75, 95% CI
-103.44 to 69.94, P 0.70), improved the glomerular filtration rate (MD: -7.00, 95% CI
-22.33 to 8.33, P  0.37) significantly compared to placebo or active control. In
addition,we found that risk ofmyocardial infarction, stroke, revascularization, and
all-cause mortality, in the B-vitamin combination therapy group was increased
(Risk Ratio 1.85, 95%CI 0.99 to 3.45, P 0.05).We also found no significant difference
between vitamin B combination therapy and control group for serious adverse
events, and one or more adverse events. CONCLUSIONS: We did not find any
improvement in kidney function, following use of vitamin B preparation. These
findings require confirmation from high quality randomized trials.
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RISK OF COMPLICATIONS IN TYPE II DIABETIC PATIENTS WITH RENAL
IMPAIRMENT: AN ANALYSIS OF THE RAMQ DATABASE
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OBJECTIVES: Chronic kidney disease is often associated with type II diabetes mel-
litus (T2DM). Patients with T2DM and chronic renal failure are at higher risk of
developing hypoglycemia or metabolic acidosis. The purpose of this study was to
identify treatment patterns in T2DM patients with chronic renal failure and to
estimate the risk of developing complications. METHODS: This study examined
data on patients covered by the Quebec provincial drug reimbursement program
(RAMQ) who had a diagnosis of diabetes, had used a hypoglycemic agent, and had
a diagnosis of chronic renal disease in the period from January 2005 to December
2010. A 1:1 control group of patients with diabetes and without renal disease,
matched for age and gender, was also created. Patients’ characteristics and drug
utilization patterns were analyzed and the risks of experiencing hypoglycemia or
metabolic acidosis were estimated. RESULTS: A total of 4889 patients who had a
diagnosis of diabetes with chronic renal failure were included in this cohort. Aver-
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